GLP-1 and Pregnancy: Washout Timing, Breastfeeding, and Unintended Exposure

Pregnancy is one of the very short list of absolute contraindications to every FDA-approved GLP-1 receptor agonist — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity). Animal reproductive toxicity data and the long half-life of weekly drugs mean that the timing of stopping matters as much as the decision to stop. The good news is that the small but growing human dataset on unintended first-trimester exposure has been reassuring rather than alarming.

Direct answer: Stop a weekly GLP-1 (semaglutide, tirzepatide, dulaglutide) at least 2 months before trying to conceive. Semaglutide has a half-life of about 1 week and remains pharmacologically active in the body for approximately 5 weeks (roughly 5 half-lives) after the final dose; tirzepatide's half-life is ~5 days, with full clearance around 25–35 days. Liraglutide (daily) clears in about 3 days. If pregnancy occurs unexpectedly while on a GLP-1, discontinue immediately and tell your obstetrician — but inadvertent first-trimester exposure is not, on current evidence, considered grounds for termination or extra fetal monitoring. Breastfeeding with injectable semaglutide is now considered probably low-risk by LactMed; oral semaglutide (Rybelsus) is contraindicated during lactation because of the SNAC absorption enhancer.

Why GLP-1s Are Contraindicated in Pregnancy

Three threads run through the manufacturer labels, FDA guidance, ACOG commentary, and UKTIS/MotherToBaby monographs.

1. Animal reproductive toxicity. In rat and rabbit studies, semaglutide caused embryofetal mortality, structural malformations, and growth alterations at exposures below or at human therapeutic levels. Tirzepatide showed similar signals. The findings are confounded by significant maternal weight loss and reduced food intake — but the FDA classifies these drugs accordingly and the labels reflect it.

2. Maternal weight loss itself. Pregnancy is not a time for active weight reduction. Caloric restriction during organogenesis (the first ~10 weeks) is associated with low birth weight and other outcomes that overlap with what GLP-1 medications cause incidentally.

3. The SNAC problem in oral semaglutide. Rybelsus uses salcaprozate sodium (SNAC) as an absorption enhancer. SNAC has its own animal toxicity signals and crosses biological membranes more readily than the peptide itself. This is why oral semaglutide has stricter restrictions in pregnancy and lactation than injectable forms.

Planning Ahead: The 2-Month Rule

The manufacturer labels for Ozempic, Wegovy, and Rybelsus recommend stopping at least 2 months before attempting pregnancy. ACOG and most reproductive endocrinologists echo this. The math:

Drug	Half-life	Approx. time to clear	Recommended stop
Semaglutide (weekly)	~1 week	~5 weeks	8 weeks before conception
Tirzepatide (weekly)	~5 days	~25–35 days	4–8 weeks before conception
Liraglutide (daily)	~13 hours	~3 days	~1 week before conception
Dulaglutide (weekly)	~5 days	~25–35 days	4–8 weeks before conception
Oral semaglutide (Rybelsus)	~1 week	~5 weeks	8 weeks before conception

The 2-month figure is the conservative, easy-to-remember version that covers the whole class. Some OB specialists prefer 3 months if you have been on high doses for a long time, to account for tissue redistribution.

Practical issues during the washout:

Some weight regain is normal. Plan for it. Continued protein intake, resistance training, and a structured plate keep regain modest.
Hunger and food noise often return within 2–3 weeks.
A1C may drift up in T2D patients. Coordinate with your endocrinologist on bridging therapy (metformin is pregnancy-compatible and often used).
Cycles may shift. Weight loss can have already restored ovulation; expect potentially faster conception than you'd predict.

If Pregnancy Happens Unexpectedly

The fastest-growing reason people end up on GLP-1s during conception is that the drugs themselves restore fertility — particularly in women with PCOS, insulin resistance, or weight-related anovulation. "Ozempic babies" is a real and rising phenomenon.

If you discover you are pregnant while on a GLP-1:

Stop the medication immediately. No taper required.
Contact your prescriber and obstetrician the same week. They will document exposure dates and dose.
Do not panic. Inadvertent first-trimester exposure to GLP-1 medications, on current data, is not grounds for termination or extra fetal monitoring beyond standard prenatal care.
Take folic acid (400–800 mcg daily) immediately if not already.
Consider enrolling in a pregnancy registry (Novo Nordisk and Eli Lilly both maintain them).

UKTIS, the UK Teratology Information Service, explicitly states that "inadvertent exposure to GLP-1 RAs at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring."

What the Human Data Actually Show

Animal data drove the contraindication, but human data is what counts for risk counseling after an unintended exposure. The 2024–2026 evidence base:

Multicentre Teratology Information Service cohort (n=168 GLP-1-exposed first-trimester pregnancies). Major birth defect rate 2.6%, versus 2.3% in a diabetes reference group and 3.9% in an overweight/obese reference group — no increased risk.
Large registry analysis of 104,422 singleton pregnancies (32 semaglutide-exposed in first trimester). Major malformation rate 9.4% on semaglutide versus 13.9% on insulin and 7.7% in unexposed. No statistically increased risk versus insulin or unexposed comparators.
Type 2 diabetes registry of ~50,000 pregnancies found no significant fetal development problems among those on a GLP-1 at conception versus those not.
Systematic review and meta-analysis (JACC Advances, 2026) of GLP-1 exposure in pregnancy: no increased risk of major congenital anomalies compared with insulin-only therapy.

The recurring caveat: sample sizes are still modest, and these data justify reassurance after accidental exposure — not deliberate continuation. Authors of every major review explicitly state the recommendation against use during pregnancy has not changed.

Breastfeeding: Injection vs Oral Is a Critical Distinction

This is where labels, LactMed, and clinical practice have evolved fastest.

Injectable semaglutide (Ozempic, Wegovy). A study of 8 nursing mothers found semaglutide was undetectable in breast milk (<1.7 mcg/L) at therapeutic doses. Infants studied (ages 4–23 months) had normal growth and development. The molecule is large (~4,100 Da) — well above the ~500 Da threshold where drugs typically transfer easily into milk — and any trace amount would be poorly absorbed by an infant's gut.

Injectable tirzepatide (Mounjaro, Zepbound). Even less data, but the same biology: a 4,800 Da protein that does not cross meaningfully into milk. InfantRisk Center reported tirzepatide was undetectable or barely detectable in milk at doses up to 5 mg, with no infant adverse effects.

Oral semaglutide (Rybelsus). Different story. The SNAC absorption enhancer is small enough to enter milk and may accumulate in infants. LactMed and most labels list oral semaglutide as avoid during breastfeeding. Injectable semaglutide is the preferred option for any breastfeeding patient where a GLP-1 is being considered.

The real-world concern with breastfeeding on any GLP-1 is not direct drug transfer — it is maternal undernutrition. GLP-1s can reduce caloric intake by 30–40%. Lactation requires ~500 extra calories per day above baseline (~2,250–2,500 daily for most women). Insufficient maternal intake risks:

Reduced milk supply
Nutrient deficiencies in milk
Maternal fatigue, dehydration, and dizziness
Slowed infant weight gain

If a GLP-1 is being used postpartum during nursing — usually only after specialist input — best practice is to wait until the baby is at least 6 months old (ideally 7–12 months, with solid foods established), track calories deliberately rather than rely on hunger cues, prioritize protein (90–120 g/day), supplement with a prenatal vitamin, and monitor the infant's growth curve closely.

Fertility Benefits Before Pregnancy

For many women, the right framing isn't "GLP-1s harm fertility" — it is "GLP-1s can restore fertility, then need to be stopped before conception." Key points:

PCOS, anovulation, and insulin resistance are the dominant causes of weight-related infertility. GLP-1s improve all three.
5–10% body weight loss is enough to restore regular ovulation in many women.
Improved insulin sensitivity reduces hyperandrogenism, can normalize cycle length, and lowers miscarriage risk in subsequent pregnancies.
Use reliable contraception while on a GLP-1 if you are not trying to conceive — fertility may rebound faster than you expect, and oral contraceptive absorption can be reduced during the first 4 weeks of tirzepatide titration.
Plan the transition off the drug 8 weeks before the conception window so the body has cleared the medication before fertilization.

Post-Pregnancy Restart Timing

After delivery, when can you restart?

Scenario	Earliest restart
Formula feeding only	Once your obstetrician clears you postpartum (typically 4–6 weeks) and you have no contraindications
Exclusive breastfeeding	Generally not recommended; wait until weaning
Combination feeding	Specialist discussion; injectable preferred over oral if used
Considering another pregnancy soon	Coordinate timing — stop 2 months before next conception window

Postpartum weight loss can be slow and emotionally loaded. Many patients consider a GLP-1 to address persistent post-pregnancy weight. The class is highly effective; the timing requires intention.

What About Pregnancy After Stopping?

A common worry: "If I was on a GLP-1, can the next pregnancy still be healthy?"

Current data say yes. Beyond the washout period, there is no evidence that prior GLP-1 use affects subsequent pregnancy outcomes. The drug is fully cleared, and any weight loss preserved generally improves pregnancy outcomes (lower gestational diabetes, preeclampsia, and macrosomia rates).

Recent observational data also suggest that women who discontinue GLP-1s before conception have pregnancy outcomes similar to women who were never exposed — once the washout has been completed.

Unintended Exposure Data: A Closer Look

Because so many people now end up briefly exposed in early pregnancy, this is worth detail.

Timing of exposure matters less than absolute exposure. The first-trimester window (weeks 5–10) is the critical organogenesis period. Exposures confined to weeks 1–4, before implantation completes, are essentially pre-organogenesis.
Stopping at positive test is the standard, evidence-supported approach. Pregnancy tests typically positive 4–5 weeks after the last menstrual period — exposure beyond this point is generally truncated quickly.
No specific extra ultrasounds, amniocentesis, or genetic testing is recommended solely because of GLP-1 exposure.
Pregnancy registries (Novo Nordisk's Wegovy/Ozempic registry, Eli Lilly's tirzepatide registry) are gathering long-term outcome data. Enrolment is voluntary and recommended.
Neonatal hypoglycemia is one theoretical late-pregnancy concern if exposure persists near delivery — relevant only in patients who continue against advice, not in those who stop in the first trimester.

What People Get Wrong

"GLP-1s cause infertility." They usually do the opposite. Most fertility issues on a GLP-1 are about needing to stop before conception, not about the drug suppressing fertility.
"One week off is enough before trying to conceive." No. Semaglutide and tirzepatide are weekly drugs precisely because they linger; 5–8 weeks of clearance is the right number.
"My pregnancy is ruined if I got exposed in early weeks." Current data are reassuring. No major signal for birth defects in modest first-trimester exposures.
"I can keep using it if I just lower the dose." No. Discontinuation is the recommendation across the entire dose range.
"Breastfeeding always rules out a GLP-1." Injectable semaglutide is now considered probably compatible with breastfeeding, with caveats around maternal nutrition. Oral semaglutide is the formulation that is firmly avoided.
"I should switch to oral semaglutide when nursing because it is safer." The opposite. SNAC in Rybelsus is the reason it is more restricted in lactation than the injection.
"If I am on birth control I do not need to worry about timing." Tirzepatide reduces oral contraceptive absorption during the first 4 weeks of titration — backup contraception is recommended then. Even more importantly: fertility can rebound rapidly once weight drops.

Frequently Asked Questions

How long before pregnancy should I stop a GLP-1? At least 2 months for semaglutide, tirzepatide, and dulaglutide. About 1 week for daily liraglutide. Some specialists prefer 3 months if you have been on high doses long term.

What is the half-life of semaglutide? About 1 week. Five half-lives — the standard time for full clearance — is approximately 5 weeks. The 2-month rule builds in a safety buffer.

I just found out I am pregnant and I am on a GLP-1. What now? Stop the medication today. Contact your obstetrician and prescriber this week. Take folic acid. Do not panic — current data are reassuring for short, early-pregnancy exposures.

Will my baby have birth defects from accidental first-trimester exposure? Current human data, including a multicentre study of 168 exposed pregnancies and a registry study covering more than 100,000 pregnancies, show no increased rate of major birth defects versus comparison groups. Sample sizes are still modest, but the signal is reassuring.

Can I breastfeed on a GLP-1? Injectable semaglutide and tirzepatide appear to transfer minimally into breast milk and current evidence shows no infant harm. The main concern is maternal caloric intake. Oral semaglutide (Rybelsus) is contraindicated during breastfeeding because of the SNAC absorption enhancer.

Will GLP-1 use before pregnancy affect my baby later? No evidence to suggest so, provided you complete the recommended washout before conception.

Can a GLP-1 help me get pregnant? Indirectly, yes. Weight loss of 5–10% and improved insulin sensitivity restore ovulation in many women with PCOS or weight-related anovulation. But the drug itself must be stopped before conception.

When can I restart a GLP-1 after delivery? If you are not breastfeeding, typically after your 4–6 week postpartum visit. If you are breastfeeding, most guidance is to wait until weaning, although injectable semaglutide is increasingly considered case-by-case with specialist input.

Last reviewed: May 13, 2026

GLP-1 and Pregnancy: Washout Timing, Breastfeeding, and Unintended Exposure (2026)